protein (ARL2BP or BART). It is an effector protein of the small GTP-binding proteins ARL2 and ARL3, and localizes to the distal part of the connecting cilium in photoreceptors and to the basal body of ciliated cells [10] . Three variants in ARL2BP in three unrelated families have been previously reported as causative of RP, with or without situs inversus [10, 11] .
The identification of disease-causing mutations in RP has been accelerated by the implementation of next-generation sequencing (NGS) technologies. For affected individuals who lack a molecular diagnosis, whole-exome sequencing (WES) and whole-genome sequencing (WGS) are effective tools for identifying new potential causative variants [12] .
In our collaborative study of unsolved cases, through the UK Inherited Retinal Disease Consortium and NIHRBioResource Rare Diseases research study, 1,051 unrelated individuals were analyzed with WES or WGS. In this report, we describe two unrelated families, with no known consanguinity, in whom WES or WGS revealed homozygous variants affecting the mRNA processing of ARL2BP.
METHODS

Clinical assessment of study families:
The study protocols adhered to the tenets of the Declaration of Helsinki and received approval from the local Ethics Committee of the participating institutions: Moorfields Eye Hospital and Oxford Eye Hospital. Written, informed consent was obtained from all participants before they were included in this study. The two probands underwent detailed clinical examination, including best-corrected decimal visual acuity (BCVA), 35-degree color fundus photography (TRC-NW8; Topcon (Great Britain) Medical Ltd., Newbury, UK), ultrawidefield confocal scanning laser imaging (Optos plc, Dunfermline, UK), fundus autofluorescence (FAF) imaging (Spectralis, Heidelberg Engineering Inc., Carlsbad, CA), and spectraldomain optical coherence tomography (SD-OCT; Spectralis, Heidelberg Engineering Inc.).
Next-generation sequencing: DNA samples for the two probands were analyzed with WES in family 1 [13] and WGS in family 2 [12] as follows. For the WES analysis, genomic DNA was processed according to the Agilent SureSelect XT Library Prep protocol (Agilent Technologies, Santa Clara, CA) with capture using a SureSelect Exome V5 Capture library. After hybridization and indexing, 100 bp paired end sequencing was performed (Illumina HiSeq 2500 sequencer, Illumina Inc., San Diego, CA). Reads were aligned to the hg19 human reference sequence (build GRCh37) using Novoalign v.2.08 (Novocraft, Selangor, Malaysia). Duplicate reads were marked with Picard tools MarkDuplicates. Variant calling was performed using GATK, creating gVCF formatted files for each sample. The final variant calling for individual gVCF files was performed using the GATK Genotype gVCFs module. The variant quality scores were then recalibrated separately for indels and single nucleotide variants (SNVs). Resulting variants were annotated using ANNOVAR based on Ensembl gene and transcript definitions. Candidate variants were filtered based on function (non-synonymous, presumed loss-of-function, or splicing) and a minor allele frequency (MAF) of <0.005 using several data sets, including an in-house exome-sequencing control data set of approximately 4,000 individuals (UCLEx), NHLBI GO Exome Sequencing Project (EVS), and 1000 Genomes phase 1 data set. Variants were further manually interrogated for variant call quality, predicted pathogenicity, and biologic plausibility. Candidate variants were then ranked, considering the likely mode of inheritance for each family, prioritizing variants with a MAF of <0.001 in the Exome Aggregation Consortium (ExAC) database [14] (accessed on 11/01/2017).
WGS was performed using an Illumina TruSeq DNA PCR-Free Sample preparation kit (Illumina, Inc.) and an Illumina HiSeq 2500, generating minimum coverage of 15X for approximately 95% of the genome. Reads were aligned to GRCh37 using Isaac Genome Alignment Software (version 01.14; Illumina, Inc.) [15] . SNVs and small insertion/deletions were identified using Isaac Variant Caller (version 2.0.17). To identify potentially pathogenic variants, a two-step variant filtering protocol was designed, using automated filtering followed by a manual review. For SNVs and indels, automated filtering identified variants that fulfill the following criteria: passes standard Illumina quality filters in >80% of the whole NIHR BioResource Rare Diseases cohort (n=6,688); predicted to be a high impact, medium impact, or splice region variant, or present in the HGMD Pro database; and had a MAF <0.01 in the control data sets, including the NIHR BioResource Rare Diseases cohort and the Exome Aggregation Consortium (ExAC) database [14] . If a variant was present in the HGMD Pro database, a higher MAF threshold of 0.1 was used. A manual review of all the variants that passed the automated filtering was then performed.
For WES and WGS, candidate variants were then prioritized based on previous association of the gene with a compatible phenotype and biologic plausibility. Phenopolis [16] , a platform for studying the pleiotropy of genes, was also used to prioritize variants. Copy number variations (CNVs) in the genomic region spanning the ARL2BP gene were assessed in the WES data using the Exome Depth calling algorithm [17] and WGS data using Isaac Copy Number Variant Caller 
In silico analysis of ARL2BP variants:
The UCSC genome browser and Phenopolis [16] were used for visualization of existing gene variants and evolutionary conservation.
Variants in ARL2BP were scored for likelihood of altering splicing using several tools: Berkeley Drosophila Genome Project Splice Site Prediction [18] , NetGene2 [19] , and Human Splice Finder.
Reverse transcriptase-PCR analysis of ARL2BP: Total RNA was extracted from whole blood using blood PAXgene Blood RNA collection tubes and a PAXgene Blood purification RNA Kit (PreAnalytix, Qiagen/BD, Hombrechtikon, Switzerland). cDNA was reverse-transcribed using a cDNA synthesis kit with an Oligo (dT) Primer mix (Tetro cDNA Syntesis kit, Bioline, Toronto, Canada). The cDNA was then amplified from exon 1 (forward primer 5′-CTT TCT CCT CCG CCT CTG AT-3′) to exon 6 (reverse primer 5′-TCA TGA GCT GAG CCT ATT GG-3′) to amplify the ARL2BP transcripts. 1 µl of cDNA and a final concentration of 0.4 µM of each primer were used for amplification in a final volume of 25 µl using Go taq Green Master Mix (Promega). Amplification was performed for 35 cycles, each cycle consisted of 30 s at 95 °C, 30 s at 62 °C, and 30 s at 72 °C. The resulting products were then gel purified (QIAquick Gel Extraction Kit, Qiagen, Hilden, Germany) and Sanger sequenced to determine the transcripts produced by alternative splicing. Quantification of different transcripts was calculated using Image Lab Software 6.0.1 (Bio-Rad, Hercules, CA).
RESULTS
ARL2BP variants identified in individuals with retinitis pigmentosa:
Using a combination of WES and WGS, variants in ARL2BP were identified in two unrelated individuals with RP. The pedigrees of the study families are shown in Figure 1A .
A simplex white female (1-II:4) from a non-consanguineous family (family 1) was diagnosed with RP aged 35 years. No other syndromic features were identified. WES was performed, and variants were filtered and prioritized as described, considering potential recessive inheritance. This identified a homozygous ARL2BP variant, c.390+5G>A, as the most compelling candidate (GRCh37 Chr16:57284424G>A, NM_012106.3: c.390+5G>A). This variant was absent in the gnomAD database [14] and was predicted by NetGene2, NNsplice, and Human Splice Finder to disrupt the donor splice site of exon 5. No CNVs were detected in ARL2BP. Sanger sequencing confirmed the variant in the affected female proband.
The proband (GC21134, 2-III:2) of family 2, from a North African non-consanguineous family (self-reported), was diagnosed with RP at age 36 years. WGS was performed as part of the NIHR-BioResource Rare Diseases research study [12] , and variants were filtered and prioritized as described considering potential recessive inheritance. A homozygous variant, c.207+1G>A, in ARL2BP (GRCh37 Chr16:57282556G>A, NM_012106.3: c.207+1G>A) was identified as the most probable cause of disease. The variant alters the invariant GT dinucleotide at the splice donor site of exon 3. This variant has an MAF of 0.0001071 in the gnomAD database [14] , consistent with an allele frequency for a recessive condition, with no homozygous individuals present in the database. The variant was predicted by NetGene2, NNsplice, and Human Splice Finder to disrupt the donor splice site of exon 3. Sanger sequencing confirmed the variant in the affected male proband. No CNVs were detected in ARL2BP.
Both variants are located at highly conserved splice donor sites in ARL2BP ( Figure 1B ).
Phenotypic comparison of affected individuals:
A white female (1-II:4) presented at 35 years of age with slow dark adaptation and mild photosensitivity. There was no family history of inherited eye disease, and general health was excellent, with no syndromic features. After 7 years of follow-up, at age 42 years, she had normal visual acuity of OD 0.04 LogMAR (6/6 Snellen equivalent) and OS 0.02 (6/6). Goldmann visual field testing at presentation showed generalized constriction to all test targets; although she was able to continue driving until 40 years of age, by which time there was moderate infero-and superotemporal constriction in the left eye and inferotemporal loss in the right eye. Fundoscopy and retinal imaging showed intraretinal bone spicule-like pigmentation mainly in the nasal retina, generalized vascular attenuation, and optic nerve pallor (Figure 2A,B) . SD-OCT showed normal macular architecture ( Figure 2E,F) , but FAF imaging revealed symmetric bilateral perimacular rings of increased signal, also extending bilaterally inferiorly and in the right eye also superiorly, with patchy reduced AF in the midperiphery (Figure 2C,D) . Electrophysiological assessment showed greater generalized rod than cone loss, with significant reduction in rod amplitudes (Appendix 1). Other investigations included normal karyotyping and normal phytanic acid levels. There were no signs of situs inversus (self-reported).
A male (2-III:2, GC21134) from a North African nonconsanguineous family presented at 36 years of age with night blindness when he was diagnosed with retinitis pigmentosa. There was no family history and no evidence of systemic illness (situs inversus not investigated). Figure 2C -H show the extensive degeneration at age 45 years (right more than left).
Fundus examination showed bilateral macular and peripheral retinal atrophy with widespread intraretinal bone spicule-like pigmentation ( Figure 2G, H) . Fundus autofluorescence (Optos) showed signal reduction at the posterior pole, around the temporal vascular arcades, and throughout the nasal retina ( Figure 2I, L) . On OCT, there was widespread loss of the outer retinal structure with some preservation of the foveal photoreceptor layer ( Figure 2M, N) , corresponding to residual autofluorescence at the fovea ( Figure 2I , L). CF=counting fingers, HM=hand motion, PL=light perception, NI=not investigated, NR=not reported. [10] , and [11] refer to previous reports in the references.
ARL2BP variants alter pre-mRNA splicing: RT-PCR analysis was performed on cDNA derived from RNA extracted from blood samples for the two affected individuals and controls, and the resulting transcripts were Sanger sequenced. ARL2BP transcripts in affected individuals were aberrantly spliced ( Figure 3 ).
In individual 1-II:4, the homozygous c.390+5G>A mutation within the donor splice site for exon 5 resulted in five different transcripts: Four transcripts revealed abnormal splicing events, including exon 5 skipping and intron 5 inclusion, predicted to result in premature termination of the protein ( Figure 3A) . Exon 5 was skipped in the most abundant transcript (representing 75.2% of the total transcript), resulting in a frameshift and premature termination p.(His99Lysfs*9; NM_012106.3). In three other aberrant transcripts, alternative acceptor and donor sites were activated, resulting in the inclusion of part of intron 5 ( Figure 3A, B) . The predicted consequence of these events is an insertion of 55 bp, 189 bp, and 509 bp resulting in p.(Glu131Glyfs*9), p.(Glu131_His163delinsGlyLysLeuLeuLeuLeuPheIle), and p.(Glu131Glyfs*9), respectively. These three aberrant transcripts represent 7.2%, 9.1%, and 1.4% of the total transcript, respectively. A normally spliced ARL2BP transcript was also detected ( Figure 3A) representing only 7.1% of the total transcript. In individual 2-III:2, only one transcript was detected that represents exon 3 skipping, predicted to lead to a frameshift and premature termination codon p.(Asp35Phefs*8; Figure 3A , B).
DISCUSSION
Davidson and colleagues [10] first described biallelic mutations in ARL2BP associated with arRP in two families. An additional family was subsequently identified by Audo et al. [11] . These studies described homozygous ARL2BP missense and splice site variants (c.101-1G>C, c.134T>G [p.Met45Arg], c.207+1G>T) in arRP cases of Arab-Muslim, European, and Moroccan origin ( Figure 1C) . In this study, we identified two novel homozygous variants in ARL2BP in two unrelated RP cases that result in aberrant pre-mRNA splicing. Interestingly, the only missense variant identified is in exon 3 [10] ( Figure 1C) , suggesting a critical function of this exon in photoreceptor homeostasis.
One variant, c.207+1G>A, identified in this study occurs at the same location as a previously described mutation c.207+1G>T [11] , and both variants cause exon 3 skipping (Figure 3) . The other two splice site variants identified, c.101-1G>C [10] and c.390+5G>A, predominantly cause abnormal splicing, but evidence of low levels of wild-type ARL2BP transcript was detected in both cases (Figure 3) [10] .
A comparison of the phenotypes described for all cases attributed to mutations in ARL2BP is presented in Table 1 . In this study, the two probands presented at similar ages, although patient 2-III:2 (GC21134), in whom no normal transcript was detected, appeared to suffer more severe loss of the central retinal structure compared to patient 1-II:4. This may indicate the consequences of a decreased rather than a complete absence of ARL2BP protein, with residual levels of wild-type transcript and protein resulting in a milder phenotype. However, in the absence of animal models, further cases need to be described before any phenotype-genotype correlations can be made for this rare condition.
APPENDIX 1. INTERNATIONAL-STANDARD FULL-FIELD ERGS AND PATTERN ERG (PERG) FOR II:4, FAMILY 1.
To access the data, click or select the words "Appendix 1."
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